These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical features of patients with bacteraemia caused by Mycobacterium avium complex species and antimicrobial susceptibility of the isolates at a medical centre in Taiwan, 2008-2014. Lee MR; Chien JY; Huang YT; Liao CH; Shu CC; Yu CJ; Hsueh PR Int J Antimicrob Agents; 2017 Jul; 50(1):35-40. PubMed ID: 28478210 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China. Zhao X; Wang Y; Pang Y Infect Genet Evol; 2014 Oct; 27():332-8. PubMed ID: 25131955 [TBL] [Abstract][Full Text] [Related]
5. Nationwide analysis of Mycobacterium chimaera and Mycobacterium intracellulare isolates: Frequency, clinical importance, and molecular and phenotypic resistance profiles. Truden S; Žolnir-Dovč M; Sodja E; Starčič Erjavec M Infect Genet Evol; 2020 Aug; 82():104311. PubMed ID: 32247868 [TBL] [Abstract][Full Text] [Related]
6. Absence of Mycobacterium intracellulare and presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease. Wallace RJ; Iakhiaeva E; Williams MD; Brown-Elliott BA; Vasireddy S; Vasireddy R; Lande L; Peterson DD; Sawicki J; Kwait R; Tichenor WS; Turenne C; Falkinham JO J Clin Microbiol; 2013 Jun; 51(6):1747-52. PubMed ID: 23536397 [TBL] [Abstract][Full Text] [Related]
7. [Genetic research about Mycobacterium avium complex]. Ogawa K Kekkaku; 2011 Feb; 86(2):61-8. PubMed ID: 21404652 [TBL] [Abstract][Full Text] [Related]
8. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex. Maurer FP; Pohle P; Kernbach M; Sievert D; Hillemann D; Rupp J; Hombach M; Kranzer K Clin Microbiol Infect; 2019 Mar; 25(3):379.e1-379.e7. PubMed ID: 29906595 [TBL] [Abstract][Full Text] [Related]
9. Identification and drug susceptibility testing of the subspecies of Mycobacterium avium complex clinical isolates in mainland China. Li Y; Liu C; Ma A; He W; Qiu Q; Zhao Y; Li Y J Glob Antimicrob Resist; 2022 Dec; 31():90-97. PubMed ID: 35660663 [TBL] [Abstract][Full Text] [Related]
10. Impact of different subspecies on disease progression in initially untreated patients with Mycobacterium avium complex lung disease. Pan SW; Shu CC; Feng JY; Chien JY; Wang JY; Chan YJ; Yu CJ; Su WJ Clin Microbiol Infect; 2021 Mar; 27(3):467.e9-467.e14. PubMed ID: 32360207 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. Boyle DP; Zembower TR; Reddy S; Qi C Am J Respir Crit Care Med; 2015 Jun; 191(11):1310-7. PubMed ID: 25835090 [TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel variant of Mycobacterium chimaera. van Ingen J; Hoefsloot W; Buijtels PCAM; Tortoli E; Supply P; Dekhuijzen PNR; Boeree MJ; van Soolingen D J Med Microbiol; 2012 Sep; 61(Pt 9):1234-1239. PubMed ID: 22700551 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. Huang CC; Wu MF; Chen HC; Huang WC J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770 [TBL] [Abstract][Full Text] [Related]
14. Different clinical features of patients with pulmonary disease caused by various Mycobacterium avium-intracellulare complex subspecies and antimicrobial susceptibility. Chang CL; Chen LC; Yu CJ; Hsueh PR; Chien JY Int J Infect Dis; 2020 Sep; 98():33-40. PubMed ID: 32534139 [TBL] [Abstract][Full Text] [Related]
15. Differences in Drug-Susceptibility Patterns between Fernandez-Pittol M; Batista-Arnau S; Román A; San Nicolás L; Oliver L; González-Moreno O; Martínez JA; Amaro-Rodríguez R; Soler N; Gené A; González-Cuevas A; Tudó G; Gonzalez-Martin J Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671265 [No Abstract] [Full Text] [Related]
16. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. Brown-Elliott BA; Iakhiaeva E; Griffith DE; Woods GL; Stout JE; Wolfe CR; Turenne CY; Wallace RJ J Clin Microbiol; 2013 Oct; 51(10):3389-94. PubMed ID: 23946523 [TBL] [Abstract][Full Text] [Related]
17. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615 [TBL] [Abstract][Full Text] [Related]
18. [Non-tuberculous mycobacteriosis. What has been coming out]. Kajiki A Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655 [TBL] [Abstract][Full Text] [Related]
19. Searching for new therapeutic options for the uncommon pathogen Mycobacterium chimaera: an open drug discovery approach. Cantillon D; Goff A; Taylor S; Salehi E; Fidler K; Stoneham S; Waddell SJ Lancet Microbe; 2022 May; 3(5):e382-e391. PubMed ID: 35544099 [TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]